All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel
.
Security |
Imputed Share Price |
Prev Shares |
Current Shares |
Change (Percent) |
Prev Value (USD x1000) |
Current Value (USD x1000) |
Change (Percent) |
AAAP / Advanced Accelerator Applications S.A
|
|
|
|
|
|
|
|
APLS / Apellis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
GNCA / Genocea Biosciences Inc
|
|
|
|
|
|
|
|
SBBP / Strongbridge Biopharma plc
|
|
|
|
|
|
|
|
0HBB / Aimmune Therapeutics Inc
|
|
|
|
|
|
|
|
AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
RGNX / REGENXBIO Inc.
|
|
|
|
|
|
|
|
ZGNX / Zogenix Inc
|
|
|
|
|
|
|
|
AUPH / Aurinia Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
BHVN / Biohaven Ltd.
|
|
|
|
|
|
|
|
MDGL / Madrigal Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
CBAY / CymaBay Therapeutics, Inc.
|
|
|
|
|
|
|
|
NBRV / Nabriva Therapeutics Plc
|
|
|
|
|
|
|
|
FOMX / Foamix Pharmaceuticals Ltd.
|
|
|
|
|
|
|
|
ASND / Ascendis Pharma A/S - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
KALV / KalVista Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
SRRA / Sierra Oncology Inc
|
|
|
|
|
|
|
|
VYNE / VYNE Therapeutics Inc.
|
|
|
|
|
|
|
|
VIRX / Viracta Therapeutics, Inc.
|
|
|
|
|
|
|
|
AMRS / Amyris Inc
|
|
|
|
|
|
|
|
KALA / KALA BIO, Inc.
|
|
|
|
|
|
|
|
ARWR / Arrowhead Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
CRSP / CRISPR Therapeutics AG
|
|
|
|
|
|
|
|
TRVN / Trevena, Inc.
|
|
|
|
|
|
|
|
KDMN / Kadmon Holdings Inc
|
|
|
|
|
|
|
|
AGRX / Agile Therapeutics, Inc.
|
|
|
|
|
|
|
|
TMBR / Timber Pharmaceuticals Inc
|
|
|
|
|
|
|
|
EIGR / Eiger BioPharmaceuticals, Inc.
|
|
|
|
|
|
|
|
SELB / Selecta Biosciences Inc
|
|
|
|
|
|
|
|
ACRS / Aclaris Therapeutics, Inc.
|
|
|
|
|
|
|
|
FIXX / Homology Medicines, Inc.
|
|
|
|
|
|
|
|
VRNA / Verona Pharma plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
SLNO / Soleno Therapeutics, Inc.
|
|
|
|
|
|
|
|
CDXS / Codexis, Inc.
|
|
|
|
|
|
|
|
ZLAB / Zai Lab Limited - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
SLNO / Soleno Therapeutics, Inc.
|
|
|
|
|
|
|
|